Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
JCO Precis Oncol
.
2023 Feb:7:e2200582.
doi: 10.1200/PO.22.00582.
Authors
Diaddin Hamdan
1
2
,
Laetitia Marisa
3
,
Camille Tlemsani
3
4
5
,
Eurydice Angeli
1
6
7
,
Michael Soussan
6
8
,
Nicolas Derive
3
,
Pierre Laurent-Puig
3
9
10
,
Guilhem Bousquet
1
6
7
Affiliations
1
Université Paris Cité, INSERM, UMR_S942 MASCOT, Paris, France.
2
Medical Oncology Department, Hôpital La Porte Verte, Versailles, France.
3
Multi-site Medical Biology Laboratory SeqOIA, Paris, France.
4
Medical Oncology Department, Hôpital Cochin, AP-HP, Paris, France.
5
Université Paris Cité, Paris, France.
6
Université Sorbonne Paris Nord, Villetaneuse, France.
7
Medical Oncology Department, AP-HP-Hôpital Avicenne, Bobigny, France.
8
Nuclear Medicine Departments, AP-HP-Hôpital Avicenne, Bobigny, France.
9
Institut of Cancer Paris CARPEM, AP-HP-Hôpital Européen Georges Pompidou, Paris, France.
10
Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris Cité, Paris, France.
PMID:
36848605
PMCID:
PMC10309575
DOI:
10.1200/PO.22.00582
No abstract available
MeSH terms
Humans
Phthalazines / therapeutic use
Piperazines / adverse effects
Precision Medicine*
Sarcoma* / drug therapy
Substances
olaparib
Phthalazines
Piperazines